menu
    • menu
    [{"orgOrder":0,"company":"Shaperon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"HY209","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Shaperon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shaperon \/ Not Applicable"},{"orgOrder":0,"company":"Shaperon","sponsor":"Dong-A ST","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shaperon \/ Dong-A ST","highestDevelopmentStatusID":"3","companyTruncated":"Shaperon \/ Dong-A ST"}]

    Find Clinical Drug Pipeline Developments & Deals by Shaperon

    Menu

    Shaperon

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shaperon

                            South Korea arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Shaperon

                            South Korea arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Dong-A ST

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Shaperon and Dong-A ST Sign MOU for Nanobody-Based New Drug Development

                            Details : The agreement aims to leverage Shaperon's nanobody development platform technology and Dong-A ST's expertise in antibodies to develop nanobody-based new drugs for treating neoplasms.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 10, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Dong-A ST

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shaperon

                            South Korea arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Shaperon

                            South Korea arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taurodeoxycholic Acid

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Shaperon Enrolls First Patient in Phase 2 U.S. Trial for Atopic Dermatitis Therapy 'Nugel'

                            Details : NuGel® is a gel type atopic dermatitis drug candidate, inhibiting NLRP3 inflammasome through GPCR19-P2X7 modulation. Its active pharmaceutical ingredient called HY209.

                            Brand Name : Nugel

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 18, 2024

                            Lead Product(s) : Taurodeoxycholic Acid

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth